Literature DB >> 27045478

MicroRNAs as novel targets and tools in cancer therapy.

Mohammed L Abba1, Nitin Patil1, Jörg H Leupold1, Marcin Moniuszko2, Jochen Utikal3, Jacek Niklinski4, Heike Allgayer5.   

Abstract

MicroRNAs (miRNAs) are currently experiencing a renewed peak of attention not only as diagnostics but also especially as highly promising novel targets or tools for clinical therapy in several different malignant diseases. Moreover, the recent discovery of competing endogenous RNAs (ceRNAs) as novel miRNA-regulators has contributed exciting insights in this regard. Therefore, this review summarizes and discusses the latest findings on (1) how miRNAs have become therapeutic targets of diverse synthetic antagonists, (2) how novel endogenous regulators of miRNAs such as ceRNAs or pseudogenes could emerge as therapeutics scavenging oncogenic miRNAs and (3) how miRNAs themselves are already, and will increasingly be, used as therapeutics. Recent advances on the importance of miRNA-target affinity and the subcellular localization of miRNAs are also discussed. The potential of these developments in different tumor entities and particular hallmarks of cancer such as metastasis, disease progression, interactions with the tumor microenvironment, or cancer stem cells are equally highlighted.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Metastasis; Stem cells; Therapy; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 27045478     DOI: 10.1016/j.canlet.2016.03.043

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

1.  Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.

Authors:  Tingting Zhang; Xiang Xue; Huixia Peng
Journal:  Mol Ther       Date:  2019-04-11       Impact factor: 11.454

2.  VELUCT, a long non-coding RNA with an important cellular function despite low abundance.

Authors:  Judit Danis; Márta Széll
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  MicroRNA-145, Wnt3a, and Dab2 Genes Expression Changes of the Cardiomyocytes in Hypercholesterolemic Rats Exposed to the Aerobic Training.

Authors:  Soran Heidari; Kamal Azizbeigi; Kaveh Bahmanpour
Journal:  Int J Mol Cell Med       Date:  2022-06-06

4.  miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.

Authors:  Chris Zhiyi Zhang; Yun Cao; Jia Fu; Jing-Ping Yun; Mei-Fang Zhang
Journal:  Mol Oncol       Date:  2016-09-20       Impact factor: 6.603

Review 5.  MicroRNAs as therapeutic targets in breast cancer metastasis.

Authors:  Fahima Danesh Pouya; Yousef Rasmi; Maria Gazouli; Eleni Zografos; Mohadeseh Nemati
Journal:  Drug Deliv Transl Res       Date:  2021-05-13       Impact factor: 4.617

6.  STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer.

Authors:  Jinlin Zhao; Xin Wang; Zeyun Mi; Xiangli Jiang; Lin Sun; Boyu Zheng; Jing Wang; Maobin Meng; Lu Zhang; Zhongqiu Wang; Junwei Song; Zhiyong Yuan; Zhiqiang Wu
Journal:  Cell Death Dis       Date:  2021-05-14       Impact factor: 8.469

7.  MiR-139-5p Targetedly Regulates YAF2 and Mediates the AKT/P38 MAPK Signaling Pathway to Alleviate the Metastasis of Non-Small Cell Lung Cancer Cells and Their Resistance Against Cisplatin.

Authors:  Yubo Yan; Xiangyuan Jin; HaoBo Sun; Sainan Pang; Xianglong Kong; Jianlong Bu; Shidong Xu
Journal:  Cancer Manag Res       Date:  2021-05-05       Impact factor: 3.989

Review 8.  Diet phytochemicals and cutaneous carcinoma chemoprevention: A review.

Authors:  Siliang Wang; Peiliang Shen; Jinrong Zhou; Yin Lu
Journal:  Pharmacol Res       Date:  2017-02-24       Impact factor: 10.334

Review 9.  Methylation and Noncoding RNAs in Gastric Cancer: Everything Is Connected.

Authors:  Irina V Bure; Marina V Nemtsova
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.

Authors:  Aleksandra Butrym; Piotr Łacina; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik; Grzegorz Mazur
Journal:  BMC Cancer       Date:  2018-01-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.